A pursuer of originality and inventiveness in China’s biotech industry
A practitioner of sustained innovation in global vaccine R&D arena
Founded in 2008. Beijing Health Guard Biotechnology, Inc. is a high-tech enterprise that specializes in R&D of novel biopharmaceuticals featuring a structure-guided design approach.
We are a top-tier player in the development of HPV vaccines in China, and are also advancing multiple innovative candidate vaccines for other infectious diseases. Core assets in our pipeline include a trivalent and a nonavalent HPV vaccine. We are also developing a 15-valent HPV vaccine, a recombinant bivalent COVID-19 vaccine, a recombinant polyvalent norovirus vaccine, a recombinant RSV vaccine and a recombinant zoster vaccine. The trivalent and nonavalent HPV vaccines are in phase III studies, which are among the first domestic candidates entering pivotal trials.
We were listed on the NEEQ (National Equities Exchange and Quotations) in 2015. with shares of the company trading under the ticker Health Guard and stock code 833575. Currently we are a member of the Innovation tier on the NEEQ, and have been added to the NEEQ market making index, NEEQ Innovation component index, NEEQ component index and NEEQ active stocks index.
Health Guard is a member of the China Association for Vaccines. Since its inception, the company has been certified as a High and New Technology Enterprise (HNTE), a 2019 Zhongguancun Leading high-tech Enterprise and a 2020 Beijing Specialized, Special and Innovative SMES.
Health Guard is constructing a commercial production plant, which is located in the Airport Industrial Park of Dian Zhong New Area, Yunnan Province and occupies an area of 93,000 square meters (75,000 square meters for construction). This commercial production plant will be equipped with facilities for both drug substance and drug product manufacturing, as well as warehouses. Once the facilities are in full operation, it’s expected that the annual production capacity will be 30 million doses for the recombinant HPV vaccines and 5 million doses for the recombinant polyvalent norovirus vaccine, respectively.